GSA Capital Partners’s Sana Biotechnology SANA Stock Holding History

GSA Capital Partners’s Portfolio SANA Stock Details SANA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$102K	Sell	29,239 -54,781	-65%	-$176K	0.01%	1620
2026 Q1	$242K	Buy	84,020 +51,798	+161%	+$204K	0.02%	1362
2025 Q4	$131K	Buy	+32,222	New	+$144K	0.01%	1501
2025 Q3	–	Sell	-102,458	Closed	-$280K	–	2043
2025 Q2	$280K	Buy	+102,458	New	+$211K	0.02%	1301
2024 Q3	–	Sell	-184,728	Closed	-$1.01M	–	1964
2024 Q2	$1.01M	Buy	184,728 +148,520	+410%	+$1.18M	0.07%	495
2024 Q1	$362K	Sell	36,208 -132,763	-79%	-$995K	0.03%	1097
2023 Q4	$689K	Sell	168,971 -371,279	-69%	-$1.37M	0.06%	598
2023 Q3	$2.09M	Buy	+540,250	New	+$2.9M	0.18%	100
2023 Q2	–	Sell	-265,372	Closed	-$868K	–	1894
2023 Q1	$868K	Sell	265,372 -62,421	-19%	-$249K	0.09%	396
2022 Q4	$1.29M	Buy	327,793 +130,816	+66%	+$640K	0.16%	104
2022 Q3	$1.18M	Buy	196,977 +101,667	+107%	+$734K	0.16%	102
2022 Q2	$613K	Sell	95,310 -40,795	-30%	-$260K	0.09%	375
2022 Q1	$1.12M	Buy	+136,105	New	+$1.1M	0.15%	138

Other funds holding SANA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marex Group London $23.6B AUM 57.16% 1-Year Est. Return

GSA Capital Partners's SANA Position: Q2 2026 in Review

GSA Capital Partners reduced its Sana Biotechnology (SANA) stake by 65% in Q2 2026, selling an estimated $176K and leaving 29,239 shares worth $102K. The position accounts for 0.01% of the portfolio, ranked #1620.

GSA Capital Partners first reported a position in SANA in Q1 2022 and has held it in 13 quarters since. The position peaked at $2.09M in Q3 2023. 211 funds tracked by Wall St. Rank hold SANA as of Q2 2026.

GSA Capital Partners held 29,239 shares of Sana Biotechnology worth $102K as of Q2 2026.
GSA Capital Partners sold 54,781 Sana Biotechnology shares in Q2 2026, an estimated $176K.
Sana Biotechnology made up 0.01% of GSA Capital Partners's portfolio in Q2 2026, its #1620 holding.
GSA Capital Partners first reported a position in Sana Biotechnology in Q1 2022 and has held it in 13 quarters since.
GSA Capital Partners's Sana Biotechnology position peaked at $2.09M in Q3 2023.
211 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.